Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on 1Spatial

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on IT service management company 1Spatial from 105.0p to 95.0p on Monday following the group's recent preliminary earnings report. Canaccord Genuity noted that 1Spatial's interim earnings had confirmed revenue of £33.4m, up 3% year-on-year, with software & SaaS sales increasing 35% to £11.5m and recurring revenues growing to 62% of total revenue, up from 56% in FY24. Service revenues, on the other hand, declined by -9% due to procurement delays.

In terms of profit, Canaccord noted that inflationary cost pressures and increased amortisation charges from recent platform R&D resulted in adjusted underlying earnings of £1.4m, down 32% year-on-year.

Despite this, the Canadian bank stated that 1Spatial's outlook offered "cautious optimism", with FY26 starting well as the group secured its third significant contract for 1Streetworks worth £500,000 with Kent County Council and a had a number of proof of concepts ongoing.

"However, management remains cognisant of persisting macro uncertainties and subsequent procurement delays. As such, we update our FY26 forecasts, modeling yoy sales growth of 9%. Whilst this is undoubtedly a more subdued short-term outlook, we are encouraged by ARR growth (+14% to £19.7m), which indicates strength in demand for its software portfolio (evidenced in consistent renewals at 93%), and provides 54% coverage of our FY26E sales estimate," said Canaccord Genuity, which kept its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.